Zoetis Inc. $ZTS Shares Sold by Neville Rodie & Shaw Inc.

Neville Rodie & Shaw Inc. lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 21.6% during the third quarter, HoldingsChannel reports. The firm owned 91,134 shares of the company’s stock after selling 25,149 shares during the quarter. Zoetis accounts for approximately 1.0% of Neville Rodie & Shaw Inc.’s investment portfolio, making the stock its 28th largest holding. Neville Rodie & Shaw Inc.’s holdings in Zoetis were worth $13,335,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Norges Bank purchased a new position in Zoetis during the second quarter worth about $809,491,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after purchasing an additional 1,995,491 shares during the period. Corient Private Wealth LLC increased its position in Zoetis by 85.9% during the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock worth $400,619,000 after purchasing an additional 1,191,840 shares during the last quarter. Impax Asset Management Group plc raised its stake in Zoetis by 362.6% during the second quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock worth $182,705,000 after purchasing an additional 922,589 shares during the period. Finally, Amundi raised its stake in Zoetis by 30.8% during the first quarter. Amundi now owns 3,595,628 shares of the company’s stock worth $575,691,000 after purchasing an additional 846,909 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.8%

NYSE:ZTS opened at $118.60 on Monday. The business’s 50-day moving average is $130.95 and its two-hundred day moving average is $145.94. The firm has a market capitalization of $52.26 billion, a PE ratio of 19.97, a price-to-earnings-growth ratio of 2.46 and a beta of 0.97. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $181.85. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The company’s revenue was up .5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Shareholders of record on Tuesday, January 20th will be given a $0.53 dividend. This represents a $2.12 annualized dividend and a yield of 1.8%. This is a positive change from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date of this dividend is Tuesday, January 20th. Zoetis’s dividend payout ratio is 33.67%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on ZTS shares. Barclays initiated coverage on Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price objective for the company. JPMorgan Chase & Co. dropped their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. KeyCorp initiated coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating for the company. Finally, BTIG Research reissued a “buy” rating and set a $160.00 target price on shares of Zoetis in a research report on Wednesday, December 3rd. Five investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $164.20.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.